Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company PharmaEssentia Corp.
DescriptionPD-1/PD-L1 antibody immunotherapy with interferon
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationLiver cancer
Indication DetailsTreat hepatocellular carcinoma (HCC)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today